Integrated Cardiac Safety: Assessment Methodologies for Noncardiac Drugs in Discovery, Development, and Postmarketing Surveillance

Integrated Cardiac Safety: Assessment Methodologies for Noncardiac Drugs in Discovery, Development, and Postmarketing Surveillance

Volumn , Issue , 2008, Pages 1-470

  Turner, J Rick ^a   Durham, Todd A ^a,b  

^a Campbell University   (United States)

^b Biostatistics and Data Management   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84889827704     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470411292     Document Type: Book

References (339)

1. American Heart AssociatiodAmerican Stroke Association, 2007, Heart disease and stroke statistics: 2007 update at-a-glance. http://www.americanheart.org/downloadable/heart/1 1667 1 1577754HS-StatsInsideText.pdf, accessed November 19.2007.
2. Anantharam, A. and Abbott, G.W., 2005, Does hERG coassemble with a p subunit? Evidence for roles of MinK and MiRPl. In Chadwick, D.J. and Goode, J. (Eds.), The hERG cardiac potassium channel: Structure, function, and long QT syndrome, Chichester, UK: John Wiley & Sons, 100-112.
3. Anderson, R.H. and Ho, S.Y., 2003, The morphology of the cardiac conduction system. In Chadwick, D.J. and Goode, J. (Eds.), Development of the cardiac conduction system, Chichester, UK: John Wiley & Sons, 6-24.
4. Anson, B.D., Weaver, J.G., Ackerman, M.J., et al., 2005, Blockade of HERG channels by HIV protease inhibitors, Lancet, 365:682-686.
5. Arlett, P., Moseley, J., and Seligman, P.J., 2005, A view from regulatory agencies. In Strom, B.L. (Ed.), Pharmacoepidemiology, 4th edition, Chichester, UK: John Wiley & Sons, 103-130.
6. Arnold, B.D.C., 2004, Regulatory aspects of pharmacovigilance. In Talbot, J. and Waller, P. (Eds.), Stephens 'detection of new adverse drug reactions, 5 th edition, Chichester, UK: John Wiley & Sons, 375-451.
7. Asano, K., Bohlmeyer, T.J., Westcott, J.Y., et al., 2002, Altered expression of endothelin receptors in failing human left ventricles, Journal qf Molecular and Cellular Cardiology, 34:833-846.
8. Ascher-Svanum, H., Zhu, B., Faries, D., Lacro, J.P., and Dolder, C.R., 2006, A prospective study of risk factors for nonadherence with antipsychotic medication in the treatment of schizophrenia, Journal qf.Clinical Psychiatry, 67:1114-1123.
9. Ascione, F.J., 2001, Principles OfscientiJic literature evaluation: Critiquing clinical drug trials, Washington, DC: American Pharmaceutical Association.
10. Augen, J., 2004, Bioinformatics in the post-genomic era: Genome, transcriptome, proteome, and information-based medicine, Boston: Addison-Wesley.
11. Avorn, J., 2006, Dangerous deception-Hiding the evidence of adverse drug effects, New England Journal of Medicine, 355:2169-2171.
12. Avorn, J., 2007, In defense of pharmacoepidemiology-Embracing the yin and yang of drug research, New England Journal ofMedicine, 357:2219-2221.
13. Bader, G.D. and Enright, A.J., 2005, Intermolecular interactions and biological pathways. In Baxevanis, A.D. and Ouellette, B.F.F. (Eds.), Bioinformatics: A practical guide to the analysis of genes andproteins, 3rd edition, Hoboken, NJ: Wiley-Interscience, 253-291.
14. Balkrishnan, R., Arondekar, B.V., Camacho, F.T., et al., 2007, Comparisons of rosiglitazone versus pioglitazone monotherapy introduction and associated health care utilization in Medicaid-enrolled patients with type 2 diabetes mellitus, Clinical Therapeutics, 29:1306-1315.
15. Ball, P., 2000, Moxifloxacin (Avelox): An 8-methoxyquinolone antibacterial with enhanced potency, International Journal of Clinical Practice, 54:329-332.
16. Barbey, J.T., Pezzullo, J.C., and Soignet, S.L., 2003, Effect of arsenic trioxide on QT interval in patients with advanced malignancies, Journal of Clinical Oncology, 21:3609-3615.
17. Bates, D.W., Cullen, D.J., Laird, N., et al., 1995, Incidence of adverse drug events and potential adverse drug events, Journal of the American Medical Association, 274:29-34.
18. Bates, D.W., Spell, N., Cullen, D.J., et al., 1997, The costs of adverse drug events in hospitalized patients, Journal of the American Medical Association, 277:307-311.
19. Berneis, K., Rizzo, M., Stettler, C., et al., 2008, Comparative effects of rosiglitazone and pioglitazone on fasting and postprandial low-density lipoprotein size and subclasses in patients with type 2 diabetes, Expert Opinion on Pharmacotherapy, 9:343-349.
20. Bernot, A,, 2004, Genome, transcriptome undproteome analysis, Chichester, UK: John Wiley & Sons. [First published in French in 2001: Translated into English by J. McClellan and S. Cure.]
21. Biomarkers Definitions Working Group, 200 1, Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework, Clinical Pharmacology and Therapeutics, 69:89-95.
22. Bjerregaard, P. and Gussak, I., 2008, Short QT syndrome. In Gussak, I. and Antzelevitch, C., (Eds.), Electrical diseases of the heart: Genetics, mechanisms, treatment, prevention, London: Springer-Verlag, 554-563.
23. Blackshear, K.L. and Kantor, B., 2007, Pathogenesis of atherosclerosis. In Murphy, J.G. and Lloyd, M.A. (Eds.), Mayo Clinic cardiology: Concise textbook, 3rd edition, Rochester, MN: Mayo Clinic Scientific Press, 699-714.
24. Bloomfield, D. and Krishna, R., 2008, Commentary on the clinical relevance of concentrationiQTc relationships for new drug candidates, Journal of Clinical Pharmacology, 48:6-8.
25. Bock, G. and Goode, J. (Eds.), 2006, Heart failure: Molecules, mechanisms and therapeutic targets, Chichester, UK: John Wiley & Sons.
26. Bogardus, S.T., Holmboe, E., and Jekel, J.F., 1999, Perils, pitfalls, and possibilities in talking about medical risk, Journal of the American Medical Association, 28: 1037-1041.
27. Bombardier, C., Laine, L., Reicin, A., et al. for the VIGOR Study Group, 2000, Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis, New England Journal of Medicine, 343:1520-1528.
28. Bond, C. (Ed.), 2004, Concordance, London: Pharmaceutical Press.
29. Borer, J.S., Pouleur, H., Abadie, E., et al., 2007, Cardiovascular safety of drugs not intended for cardiovascular use: Need for a new conceptual basis for assessment and approval, European Heart Journal, 28: 1904-1909.
30. Bosworth, H.B., Oddone, E.Z., and Weinberger, M. (Eds.), 2005, Patient treatment adherence: Concepts, interventions, and measurement, Mahwah, N.J.: Lawrence Erlbaum Associates.
31. Bosworth, H.B., Weinberger, M, and Oddone, E.Z., 2006, Introduction. In Bosworth, H.B., Oddone, E.Z., and Weinberger, M. (Eds:), Patient treatment adherence: Concepts, interventions, and measurement, Mahwah, N.J.: Lawrence Erlbaum Associates.
32. Bowers, D., House, A,, and Owens, D, 2006, Understanding clinical papers, 2nd edition, Chichester, UK: John Wiley & Sons.
33. Bradford Hill, A,, (1965), The environment and disease: Association or causation? Proceedings of the Royal Society of Medicine, 58:285-300.
34. Brass, E.P., Lewis, R.J., Lipicky, R., Murphy, J., and Hiatt, W.R., 2006, Risk assessment in drug development for symptomatic indications: A framework for the prospective exclusion of unacceptable cardiovascular risk, Clinicul Pharmacology and Therapeutics, 79: 165-172.
35. Breckenridge, A,, 2004, Foreword. In Talbot, J. and Waller, P. (Eds.), 2004, Stephens 'detection of new adverse drug reactions, 5Ih edition, Chichester, UK: John Wiley & Sons, xi-xii.
36. Brenner, G.M. and Stevens, C.W., 2006, Pharmacology, 2"d edition, Philadelphia: SaundersiElsevier.
37. Britten, N. and Weiss, M., 2004, What is concordance? In Bond, C. (Ed.), Concordance, London: Pharmaceutical Press, 9-28.
38. Bryson, B., 2004, A short history of nearly everything, New York: Black Swan.
39. Bunch, T.J. and Ackerman, M.J., 2007, Cardiac channelopathies. In Murphy, J.G. and Lloyd, M.A. (Eds.), Mayo clinic cardiology: Concise Textbook, 3rd edition, Rochester, MN: Mayo Clinic Scientific Press, 335-344.
40. Byerly, M.J., Nakonezny, P.A., and Lescouflair, E., 2007, Antipsychotic medication adherence in schizophrenia, Psychiatry Clinical North America, 30:437-452.
41. Cabell, C.H., Noto, T.C., and Krucoff, M.W., 2005, Clinical utility ofthe Food and Drug Administration Electrocardiogram Warehouse: A paradigm for the critical pathway initiative, Journal qfBlectrocardiographI,, 38(4 Suppl): 175-179.
42. Camm, A.J., Malik, M., and Yap, Y.G., 2004, Acquired long QTsyndrome, Malden, MA: FuturaiBlackwell Publishing.
43. Campbell, M.J., Machin, D., and Walters, S.J., 1999, Medical statistics, 3rd edition, Chichester, UK: John Wiley & Sons.
44. Campbell, M.J. and Machin, D., 2005, Design of studies for medical research, Chichester, UK: John Wiley & Sons.
45. Catterall, W.A., 2006, The voltage-gated ion channel superfamily. In Triggle, D.J., Gopalakrishnan, M., Rampe, D., and Zheng, W. (Eds.), Voltage-gated ion channels as drug targets, Manheim, Germany: Wiley-VCH, 7-18.
46. Cavalli, A., Poluzzi, E., De Ponti, F., and Recanatini, M., 2002, Toward a pharmacophore for drugs inducing the long QT syndrome: Insights from a CoMFA study of hERG K(+) channel blockers, Journal of Medicinal Chemistry, 45: 3844-3853.
47. Chadwick, D.J. and Goode, J. (Eds.), 2003, Development of the cardiac conduction system, Chichester, UK: John Wiley & Sons. (Novartis Foundation Symposium 266.)
48. Chadwick, D.J. and Goode, J. (Eds.), 2005, The hERG cardiac potassium channel: Structure, function, and long QT syndrome, Chichester, UK: John Wiley & Sons.
49. Chan, K.A. and Jones, S.C., 2007, NSAIDS-COX-2 Inhibitors-Risks and benefits. In Mann, R. and Andrews, E. (Eds.), Pharmacovigilance, 2nd edition, Chichester, UK: John Wiley & Sons, 583-402.
50. Chen, F.C. and Brozovich, F.W., 2007, Chronic stable angina. In Murphy, J.G. and Lloyd, M.A. (Eds.), Mayo clinic cardiology: Concise textbook, 3rd edition, Rochester, MN: Mayo Clinic Scientific Press.
51. Chernew, M.E., Shah, M.R., Wegh,A., et al., 2008, Impact ofdecreasing copayments on medication adherence within a disease management environment, Health Affairs, 27: 103-112.
52. Chow, S-C. and Liu, J-P., 2004, Design and analysis of clinical trials: Concepts and methodologies, 2nd edition, Hoboken, NJ: John Wiley & Sons.
53. Chuang-Stein, C., 1992, Summarizing laboratory data with different reference ranges in multi-center trials, Drug Information Journal, 26:77-84.
54. Clatworthy, J., Bowskill, R., Rank, T., Parham, R., and Horne, R., 2007, Adherence to medication in bipolar disorder: A qualitative study exploring the role of patients' beliefs about the condition and its treatment, Bipolar Disorders, 9: 656-664.
55. Clemen, R.T., 1996, Making hard decisions: An introduction to decision analysis, 2"d edition, Belmont, CA:Duxbury Press.
56. Cobert, B., 2007, Manual of drug safety and pharmacovigilance, Sudbury, MA: Jones and Bartlett Publishers.
57. Cohen, M.R. (Ed.), 2007a, Medication errors, 2"" edition, Washington, DC: American Pharmacists Association.
58. Cohen, M.R., 2007b, Causes of medication errors. In Cohen, M.R. (Ed.), Medication Errors, 2"" edition, Washington, DC: American Pharmacists Association, 55-66.
59. Couderc, J-P. and Zareba, W., 2005, Assessment of ventricular repolarization from body-surface ECGs in humans. In Morganroth, J.M. and Gussak, I. (Eds.), Cardiac safety of noncardiac drugs: Practical guidelines for clinical research and drug development, Totowa, NJ: Humana Press Inc., 107-129.
60. Culley, C.M., Lacy, M.K., Klutman, N., and Edwards, B., 2001, Moxifloxacin: Clinical efficacy and safety, American Journal of Health Systems Pharmacists, 58:379-388.
61. Curran, M.E., Splawski, I., Timothy, K.W., Vincent, G.M., Green, E.D., and Keating, M.T., 1995, A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome, Cell, 80:795.
62. Dale, J.W. and von Schantz, M., 2002, From genes to genomes: Concepts and applications of DNA technology, Chichester, UK: John Wiley & Sons.
63. Davis, N.M. and Cohen, M.R., 1981, Medication errors: Causes and prevention, Philadelphia: George F. Stickley.
64. Dawkins, R., 1999, The blind watchmaker: Why the evidence of evolution reveals a universe without design, New York: W.W. Norton & Company.
65. Dayan, C.M. and Wraith, D.C., 2008, Preparing for first-in-man studies: The challenges for translational immunology post-TGN 141 2, Clinical Experimental Immunology, 151:231-234.
66. De Ponti, F., 2008, Pharmacological and regulatory aspects of QT prolongation. In Vaz, R.J. and Klabunde, T. (Eds.), Antitargets: Prediction and Prevention of drug side efects, Weinheim, Germany: Wiley-VCH.
67. De Smet, P.A., Denneboom, W., Kramers, C., and Grol, R., 2007, A composite screening tool for mediation reviews of outpatients: General issues with specific examples, Drugs & Aging, 24:733-760.
68. Dessertenne, F., 1966, La tachycardia ventriculaire a deux foyers opposees variable, Arch Ma1 Coeur Vaiss, 59:263-272.
69. Devlin, T.M., 2006, Eukaryotic cell structure. In Devlin, T.M. (Ed.), Textbook of biochemistry with clinical correlations, 6th edition, Hoboken, NJ: John Wiley & Sons, 1-22.
70. Dhillon, S. and Gill, K., 2006, Basic pharmacokinetics. In Dhillon, S. and Kostrzewski, A. (Eds.), Clinical pharmacokinetics, London: Pharmaceutical Press.
71. Diamond, G.A., Bax, L., and Kaul, S., 2007, Perspective: Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death, Annals of Internal Medicine, 147:578-581.
72. Doering, C. and Zamponi, G., 2006, Overview of voltage-gated calcium channels. In Triggle, D.J., Gopalakrishnan, M., Rampe, D., and Zheng, W. (Eds.), 2006, Voltagegated ion channels as drug targets, Weinheim, Germany: Wiley-VCH, 65-99.
73. Doggrell, S.A., 2008, Clinical trials with thiazolidinediones in subjects with type 2 diabetes-Is pioglitazone any different from rosiglitazone? Expert Opinion on Pharmacotherapy, 9:405-420.
74. Dormandy, J.A., Charbonnel, B., Eckland, D.J., et al., 2005, Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial in macroVascular Events): A randomised controlled trial, Lancet, 366: 1279-1289.
75. Dowell, J., 2004, The prescriber's perspective. In Bond, C. (Ed.), Concordance, London: Pharmaceutical Press. 49-70.
76. Durham, T.A. and Turner, J.R., 2008, Introduction to statistics in pharmaceutical clinical trials, London: Pharmaceutical Press.
77. Edelson, E., 1999, Gregor Mendel and the roots of genetics, New York: Oxford University Press.
78. Elkins, S., Crumb, W.J., Sarazan, R.D., Wikel, J.H., and Wrighton, S.A., 2002, Three-dimensional quantitative structure-activity relationship for inhibition of human ether-a-go-go-related gene potassium channel, Journal of Pharmacology and Experimental Therapeutics, 301:427-434. [ EMEA CPMP] European Medicines Agency, Committee for Proprietary Medicinal Products, 200 1, Points to Consider on Application with 1. Meta-Analyses and 2. One Pivotal Study, http:liwww.emea.europa.eu/pdfs/human/ewpl233099fen.pdf.
79. Epstein, R.J., 2003, Human molecular biology: An introduction to the molecular basis of health and disease, Cambridge, UK: Cambridge University Press.
80. Extramiana, F., Haggui, A., Maison-Blanche, P., et al., 2007, T-wave morphology parameters based on principal component analysis reproducibility and dependence on T-offset position, Annals of Noninvasive Electrocardiology, 12: 354-363.
81. Faich, G.A. and Stemhagen, A., 2005, Cardiac arrhythmia assessments in Phase IV clinical studies. In Morganroth, J.M. and Gussak, I., (Eds.), Cardiac safety of noncardiac drugs: Practical guidelines for clinical research and drug development, Totowa, NJ: Humana Press Inc., 229-237.
82. FDA, 2005a, White Paper: Prescription Drug User Fee Act (PDUFA): Adding Resources and Improving Performance in FDA Review of New Drug Applications [see www. fda.gov].
83. FDA, 2005b, Guidance for Industry: Premarketing risk assessment [see www.fda.gov].
84. FDA, 2005c, Guidance for Industry: Good pharmacovigilance practices and phurmacorpidemiologic assessment [see www. fda.gov].
85. FDA, 2005d, Guidance for Industry: Development and use of risk minimization action plans [see www.fda.gov].
86. FDA, 2006, Guidance for Industry: Reports on the status of postmarketing study commitments-Implementation of Section 130 of the Food and Drug Administration Modernization Act of 1997 [see www.fda.gov].
87. FDA, 2007, Guidance for clinical investigators, sponsors, andlRBs (Druf): Adverse event reporting-Improving human subject protection [see www. fda.gov].
88. FDA, 2008, The Sentinel Initiative: National Strategy for Monitoring Medical Product Safety, http:llwww.fda.govloclinitiativesladvance~reportsl report0508.pdf, accessed August I, 2008.
89. Ficker, E., Dennis, A., Kuryshev, Y., Wible, B.A., and Brown, A.M., 2005, hERG channel trafficking. In Chadwick, D.J. and Goode, J. (Eds.), Symposium on the hERG cardiac potassium channel: Structure, function, and long QT syndrome, Chichester, UK: John Wiley & Sons, 57-69.
90. Finkle, J., 2008, QT assessment for oncology drugs. Presentation given during a Webinar entitled Cardiac safety in large molecules: New regulatory expectations, new strategies, February 26 [see Section 7.20 for more details.]
91. FitzGerald, G.A., 2003, COX-2 and beyond: Approaches to prostaglandin inhibition in human disease, Nature Review Drug Discovery, 2:879-890.
92. Fletcher, R.H. and Fletcher, S.W., 2005, Clinical epidemiology: The essentials, 4Ih edition, Baltimore, MD: Lippincott Williams & Wilkins.
93. Fogoros, R.N., 2006, Electrophysiologic testing, 4Ih edition, Maiden, MA: Blackwell Publishing.
94. Folb, P.I., 2006, Animal tests as predictors of human response. In Lee, C-J., Lee, L.H., Wu, C.L., Lee, B.R., and Chen, M-L. (Eds.), Clinical trials of drugs and biopharmaceuticals, Boca Raton, FL: Taylor & Francis, 3:1-55.
95. Friedman, L.M., Furberg, C.D., and DeMets, D.L., 1998, Fundamentals of clinical trials, 3rd edition, New York: Springer.
96. Gad, S.C., 2002, Drug safety evaluation, Hoboken, NJ: John Wiley & Sons.
97. Gad, S.C., 2006, Statistics and experimental design for toxicologists and pharmacologists, 4Ih edition, Boca Raton, FL: CRC Press.
98. Gaita, F., Giustetto, C., Bianchi, F., et al., 2003, Short QT syndrome: A familial cause of sudden death, Circulation, 108:965-970.
99. Gallin, J.I. (Ed.), 2002, Principles and practice of clinical research, Burlington, MA: Academic Press.
100. Gallion, S.L., Beresford, A., and Bey, P., 2005, Parallel lead optimization. In Handen, J.S. (Ed.), Industrialization of drug discovery: From target selection through lead optimization, Boca Raton, FL: Taylor & Francis, 137-163.
101. Garattini, S. and Liberati, A,, 2000, The risk of bias from omitted research, British Medical Journal. 321:845-846.
102. Gardner, S.N. and Schultz, D., 2007, The postmarket surveillance of medical devices: Meeting the challenge. In Brown, S.L., Bright, R:A., and Tavris, D.R. (Eds.), Medical device epidemiology and surveillance, Chichester: John Wiley & Sons, 482-486.
103. Garnett, C.E., Beasley, N., Bhattaram, V.A., et al., 2008, Concentration-QT relationships play a key role in the evaluation of proarrhythmic risk during regulatory review, Journal of Clinical Pharmacology, 48: 13-8.
104. Gauvin, D.V., Tilley, L.P., Smith, F.W., Jr., and Baird, T.J., 2006, Electrocardiogram, hemodynamics, and core body temperatures of the normal freely moving laboratory beagle dog by remote radiotelemetry, Journal of Pharmacological and Toxicological Methods, 53: 128-139.
105. Gerstein, H.C., Yusuf, S., Bosch, J. et al. for the DREAM Trial Investigators, 2006, Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: A randomised controlled trial, Luncet, 368:1096-1105. [Erratum, Lancet, 368:1170]
106. Ghose, A.K., Viswanadhan, V.N., and Wendoloski, J.J., 1999, A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases, Journal ojCombinatoria1 Chemistry, 155-68.
107. Glantz, L.H. and Annas, G.J., 2008, The FDA, preemption, and the Supreme Court, New England Journal of Medicine, 358: 1883-1885.
108. Glasser, S.P., Salas, M., and Delzell, E., 2007, Importance and challenges of studying marketed drugs: What is a Phase 1V study? Common clinical research designs, registries, and self-reporting systems, Journal of Clinical Pharmacology, 47: 107:410-86.
109. Glitz, D., 2006, Protein synthesis: Translation and posttranslational modifications. In Devlin, T.M. (Ed.), Textbook of biochemistry with clinical correlations, 61h edition, Hoboken, NJ: John Wiley & Sons, 201-244.
110. Goldstein, D.B., Tate, S.K., and Sisodiya, S.M., 2003, Pharmacogenetics goes genomic, Nature Reviews Genetics, 4:937-947. [Erratum in Nature Reviews Genetics, 5:76]
111. Gopalakrishnan, M., Shieh, C-C., and Chen, J., 2006, Potassium channels: Overview of molecular, biophysical, and pharmacological properties. In Triggle, D.J., Gopalakrishnan, M., Rampe, D., and Zheng, W. (Eds.), Voltage-gated ion channels as drug targets, Manheim, Germany: Wiley-VCH, 193-213.
112. Gordon-Lubitz, R.J., 2003, Risk communication: Problems of presentation and understanding, Journal of the American Medical Association, 289:95.
113. Greaves, P., 2007, Histopathology of preclinical toxicity studies, 3rd edition, New York: Academic Press/Elsevier.
114. Guess, H.A., 2005, Premarketing applications of pharmacoepidemiology. In Strom, B.L. (Ed.), Pharmacoepiderniology, 4'h edition, Chichester, UK: John Wiley & Sons, 391-400.
115. Gussak, I., Brugada, P., Brugada, J., et al., 2000, Idiopathic short QT interval: A new clinical syndrome? Cardiology, 94:99-102.
116. Gussak, I. and Antzelevitch, C. (Eds.), 2003, Cardiac repolarization: Bridging basic and clinical science, New York: Springer-Verlag.
117. Halpern, S.D. and Berlin, J.A., 2005, Beyond conventional publication bias: Other determinants of data suppression. In Rothstein, H.R., Sutton, A.J., and Borenstein, M., (Eds.), Publication bias in meta-analysis: Prevention, assessment and adjustments, Chichester, UK: John Wiley & Sons, 303-317.
118. Hancox, J.C. and Mitcheson, J.S., 2006, Combined hERG channel inhibition and disruption of trafficking in drug-induced long QT syndrome by fluoxetine: A case-study in cardiac safety pharmacology, British Journal of Pharmacology, 149:457-459.
119. Harman, R.J., 2004, Development and control of medicines and medical devices, London: Pharmaceutical Press.
120. Harrison-Woolrych, M. and Coulter, D.M., 2007, PEM in New Zealand. In Mann, R. and Andrews, E. (Eds.), Pharmacovigilance, 2"d edition, Chichester, UK: John Wiley & Sons, 317-332.
121. Haverkamp, W., Breithardt, G., Camm, A.J., et al., 2000, The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: Clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology, European Heart Journal, 21: 1216-1231. [This paper was also published in Cardiovascular Research, 2000,47:2 19-233.1
122. Haynes, R.B., Sackett, D.L., Guyatt, G.H., and Tugwell, P., 2006, Clinical epidemiology: How to do clinical practice research, 3rd edition, Philadelphia: Lippincott Williams & Wilkins.
123. Hellman, B., 2006, General toxicology. In Mulder, G.J. and Denker, L. (Eds.), Pharmaceutical Toxicology, London: Pharmaceutical Press, 1-39.
124. Herxheimer, A,, 1986, Consumer organizations. In Inman, W.H.W. (Ed.), Monitoringfor drug safety, 2'Id edition, Hingham, MA: MTP Press, 699-704.
125. Hiatt, W.R., 2006, Observational studies of drug safety-Aprotinin and the absence of transparency, New England Journal of Medicine, 355:2171-2173.
126. Ho, R.J.Y. and Gibaldi, G., 2003, Biotechnology and biopharmaceuticals: Trans forming proteins and genes into drugs, Wein heim: Wi ley-LI S S.
127. Hollister, A.S. and Montague, T.H., 2005, Statistical analysis plans for ECG data: Controlling the intrinsic and extrinsic variability in QT data. In Morganroth, J.M. and Gussak, I. (Eds.), Cardiac safety of noncardiac drugs: Practical guidelines,for clinical research and drug development, Totowa, NJ: Humana Press Inc. 239-257.
128. Holmes, M.R., Ramkissoon, K.R., and Giddings, M.C., 2005, Proteomics and protein identification. In Baxevanis, A.D. and Ouellette, B.F.F. (Eds.), Bioinformutics: A practical guide to the analysis of genes and proteins, 3'd edition, Hoboken, NJ: Wiley-Interscience, 445-472.
129. Home, P.D., Pocock, S.J., Beck-Nielsen, H., et al. for the RECORD Study Group, 2005, Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): Study design and protocol, Diabetologia, 48:1726-1735.
130. Home, P.D., Pocock, S.J., Beck-Nielsen, H., et al. for the RECORD Study Group, 2007, Rosiglitazone evaluated for cardiovascular outcomes: An interim analysis, New England Journal of Medicine, 357:28-38.
131. Homon, C.A. and Nelson, R.M., 2006, High-throughput screening: Enabling and influencing the process of drug discovery. In Smith, C.G. and O'Donnell, J.T. (Eds.), The process of new drug discovery and development, 2nd edition, New York: Informa Healthcare. 79-102.
132. Hondeghem, L.M., 2005, TRlad: Foundation for proarrhythmia (triangulation, reverse use dependence and instability). In Chadwick, D.J. and Goode, J. (Eds.), The hERG cardiac potassium channel: Structure, function, and long QT syndrome, Chichester, UK: John Wiley & Sons, 235-244.
133. Hondeghem, L.M., 2007, Relative contributions ofTRIad and QT to proarrhythmia, Journal of Cardiovascular Electrophysiology, 18:655-657.
134. Hondeghem, L.M., 2008, Use and abuse of QT and TRIaD in cardiac safety research: Importance of study design and conduct, European Journal of Pharmacology, 584: 1-9.
135. Hondeghem, L.M., De Clerk, F., and Camm, J., 2007, Short patent lives jeopardize drug and patient safety, Journal of Cardiovascular Pharmacology, 50:353-357.
136. Home, R. and Weinman, J., 2004, The theoretical basis of concordance and issues for research. In Bond, C., (Ed.), Concordance, London: Pharmaceutical Press, 119-145.
137. Huttmacher, M.M., Chapel, S., Agin, M.A., Fleishaker, J.C., and Lalonde, R.L., 2008, Performance characteristics for some typical QT study designs under the ICH-E 14 guidance, Journal of Clinical Pharmacolo 8:215-224.
138. ICH Guidance E14, 2005, The clinical evaluation of QTiQTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs (see http://www.ich.org/LOB/media/MEDIA 1476.pdf)
139. ICH Guidance S7A, 2001, Safety pharmacology studies for human pharmaceuticals (see http://www.ich.org/LOB/media/MEDIA504.pdf).
140. ICH Guidance S7B, 2005, The non-clinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals (see http://www. ich.org/LOB/media/MEDIA2 1 92.pdf).
141. [IHGS] International Human Genome Sequencing Consortium, 2001, Initial sequencing and analysis of the human genome, Nature, 409:860-921.
142. [IHGS] International Human Genome Sequencin Consortium, 2004, Finishing the euchromatic zsequence of the human genome, Nature, 431:931-945.
143. Ingelman-Sundberg, M., 2008, Editorial: Pharmacogenomic biomarkers for prediction of severe adverse drug reactions, New England Journal of Medicine, 358:1637-639.
144. Inman, W.H.W., 1981a, Postmarketing surveillance of adverse drug reactions in general practice. I: Search for new methods, British Medical Journal, 282: 1131-1132.
145. Inman, W.H.W., 1981 b, Postmarketing surveillance of adverse drug reactions in general practice. 11: Prescription-event monitoring at the University of Southampton, British Medical Journal, 282: 1126-1127.
146. Inman, W.H.W., Rawson, N.S.B., and Wilton, L.V., 1986, Prescription-event In Inman, W.H.W. (Ed.), Monitoring for drug safety, monitoring. 2"" edition, Hingham, MA: MTP Press, 213-235.
147. Inman, W.H.W. and Weber, J.C.P., 1986, The United Kingdom. In Inman, W.H.W. (Ed.), Monitoring for drug safety, 2"" edition, Hingham, MA: MTP Press, 13-47.
148. Institute of Medicine of the National Academies, 2000, To err is human: Building a safer health system, Washington, DC: National Academies Press.
149. Institute of Medicine of the National Academies, 2001, Crossing the quality chasm: A new health care system for the 21" centug Washington, DC: National Academies Press.
150. Institute of Medicine of the National Academies, 2004, Patient safety: Achieving a new standardfor care, Washington, DC: National Academies Press.
151. Institute of Medicine of the National Academies, 2007a, Preventing medication errors, Washington, DC: National Academies Press.
152. Institute of Medicine of the National Academies, 2007b, Thefuture ofdrug safety: Promoting and protecting the health of the public, Washington, DC: National Academies Press.
153. Loannidis, J.P.A., 2005, Why most published research findings are false, PLoS Medicine, 2(8):e 124.
154. Jamshidi, N., Vo, T.D., and Palsson, B.O., 2007, In silico analysis of SNPs and other high-throughput data. In Zhang, J. and Rokosh, G. (Eds.), Cardiac gene expression: Methods andprotocols, Totowa, NJ: Humana Press, 267-285.
155. JNC 7 Express, 2003, Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure (Express version). http:iiwww.nhlbi.nih.goviguidelinesihypertension/express.pdf, accessed April 29, 2008.
156. JNC 7,2004, Seventh Report ofthe Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. http:llwww.nhlbi.nih.govi guidelineslhypertension/jnc7fdl.pdf, accessed April 29,2008.
157. Jongeneel, C.V., Iseli, C., Stevenson, B.J., et al., 2003, Comprehensive sampling of gene expression in human cell lines with massively parallel signature sequencing, Proceedings of the National Academy of Sciences, 100:4702-4705.
158. Jost, N., Papp, J.G., and Varro, A., 2007, Slow delayed rectifier potassium current (I,,) and the repolarization reserve, Annals of Noninvasive Electrocardiology, 12:64-78.
159. Kahn, S.E., Haffner, S.M., Heise, M.A., et al., 2006, Gycemic durability of rosiglitazone, metformin, or glyburide monotherapy, New England Journal qf Medicine, 355:2427-2443. [Erratum, New England Journal of Medicine, 2007, 356: 1387-1 388.1
160. Kaitin, K.I., 2008, Tujh CSDD annual report on trends in drug development: Are efforts to books R&D eficiency working? Presentation given at the 6Ih Annual Partnering with Central Labs, ECG, and Imaging Labs Conference, Orlando, Florida, January 24Ih.
161. Kanagala, R., 2007, Sudden cardiac death. In Murphy, J.G. and Lloyd, M.A. (Eds.), Mayo clinic cardiology: Concise textbook, 3'* edition, Rochester, MN: Mayo Clinic Scientific Press, 493-505.
162. Kang, J., Chen, X.L., Wang, H., et al., 2005, Discovery of a small molecule activator of the human ether-a-go-go-related gene (hERG) cardiac K+ channel, Molecular Pharmacology, 67:827-836.
163. Kannel, W.B. and Sorlie, P., 1975, Hypertension in Framingham. In Paul, 0. (Ed.), Epidemiology and control of hypertension, New York: Grune & Stratton/Intercontinental Medical Book Corporation.
164. Kaplan, E.L. and Meier, P., 1958, Nonparametric estimation from incomplete observations, Journal of the American Statistical Association, 53:457-481.
165. Karkouti, K., Beattie, W.S., Dattilo, K.M., et al., 2006, A propensity score casecontrol comparison of aprotinin and tranexamic acid in high-transfusion-risk cardiac surgery, Transfusion, 46:327-338.
166. Katz, D.L., 2001, Clinical epidemiology & evidence-based medicine: Fundamental principles of clinical reasoning & research, Thousand Oaks, CA: Sage Publications.
167. Kay, R., 2007, Statistical thinking for non-statisticians in drug regulation, Chichester, UK: John Wiley & Sons.
168. Kennelly, P.J. and Rodwell, V.W., 2006a, Proteins: higher orders of structure. In Murray, R.K., Granner, D.K., and Rodwell, V.W. (Eds.), Harper b illustrated biochemisfv, 27Ih edition, New York: Lange Medical BooksiMcGraw-Hill, 30-40.
169. Kennelly, P.J. and Rodwell, V.W., 2006b, Enzymes: Mechanisms of action. In Murray, R.K., Granner, D.K., and Rodwell, V.W. (Eds.), Harper j. illustrated biochemistry, 27"' edition, New York: Lange Medical BooksiMcGraw-Hill, 49-60.
170. Kim, E.Y., Han, H.R., Jeong, S., et al., 2007, Does knowledge matter? Intentional medication nonadherence among middle-aged Korean Americans with high blood pressure, Journal of Cardiovascular Nursing, 22:397-404.
171. Korobkin, R., 2007, Perspective: Who should protect the public? The Supreme Court and medical device regulation, New England Journal of Medicine, 357: 1680-1681.
172. Korolkova, Y.V., Tseng, G.N., and Grishin, E.V., 2004, Unique interaction of scorpion toxins with the hERG channel, Journal of Molecular Recognition, 17: 209-217.
173. Kovacs, R.J., 2008, Clinical reality. Presentation given at a workshop conducted by Biomedical Sciences entitled Current issues in drug development from a cardiac safety perspective, Durham, NC, March 6,2008.
174. Krall, M.D., 2007, Letter to the Editor, New England Journal of Medicine, 357: 1776-1777.
175. Krynetskiy, E. and McDonnell, P., 2007, Building individualized medicine: Prevention of adverse reactions to warfarin therapy. Journal of Pharmacology and Experimental Therapeutics, 322:427-434.
176. Lagrutta, A.A. and Salata, J.J., 2006, Ion channel safety issues in drug development. In Triggle, D.J., Gopalakrishnan, M., Rampe, D., and Zheng, W. (Eds.), 2006, Voltage-gated ion channels as drug targets, Manheim: Wiley-VCH, 444-465.
177. Lasser, K.E., Seger, D.L., Yu, D.T., et al., 2006, Adherence to black box warnings for prescription medications in outpatients, Archives of Internal Medicine, 166: 338-344.
178. Layton, D., Key, C., and Shakir, S.A., 2003, Prolongation of the QT interval and cardiac arrhythmias associated with cisapride: Limitations of the pharmacoepidemiological studies conducted and proposals for the future, Pharmacoepidemiology and Drug Safety, 12:31-40.
179. Leader, B., Baca, Q.J., and Golan, D.E., 2008, Protein therapeutics: A summary and pharmacological classification, Nature Reviews Drug Discovery, 7:21-39.
180. Leape, L.L., 2007, Systems analysis and redesign: The foundation of metical error prevention. In Cohen, M.R. (Ed.), Medication Errors, 2"d edition, Washington, DC: American Pharmacists Association Leishman, D. and Waldron, G., 2006, Assay technologies: Techniques available for quantifying drug-channel interactions. In Triggle, D.J., Gopalakrishnan, M., Rampe, D., and Zheng, W. (Eds.), Voltage-gated ion channels as drug targets, Manheim, Germany: Wiley-VCH, 37-63.
181. Li, J. and Hidalgo, I.J., 2006, The evolving role of the Caco-2 cell model to estimate intestinal absorption potential and elucidate transport mechanisms. In Smith, C.G. and O'Donnell, J.T. (Eds.), The process of new drug discovery and development, Pd edition, New York: Informa Healthcare USA, 161-186.
182. Li, Y., Cianchetta, G., and Vaz, R.J., 2006, Structural and ligand-based models for hERG and their application in medicinal chemistry. In Triggle, D.J., Gopalakrishnan, M., Rampe, D., and Zheng, W. (Eds.), Voltage-gated ion channels as drug targets, Manheim, Germany: Wiley-VCH, 428-443.
183. Lin, Y-L. and Chan, K., 2008, Pharmacokinetic and pharmacodynamic characterization of non-antiarrhythmic QT-prolonging drugs associated with torsades de pointes, Drug Information Journal, 42:211-219.
184. Lipinski, C.A., Lombardo, F., Dominy, B.W., and Feeney, P.J., 2001, Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings, Advanced Drug Delivery Reviews, 46: 3-26.
185. Litwin, J.S., Kleiman, R.B., and Gussak, I., 2008, Acquired (drug-induced) long QT syndrome. In Gussak, I. and Antzelevitch, C. (Eds.), Electrical diseuses of the heart: Genetics, mechanisms, treatment, prevention, London: Springer-Verlag, 705-718.
186. Lo Re, V., 111 and Strom, B.L., 2007, The role of academia and the research community in assisting the Food and Drug Administration to ensure US drug safety, Pharmacoepidemiology and Drug Safety, 16:818-825.
187. Lohr, K.N., 2007, Emerging methods in comparative effectiveness and safety: Symposium overview and summary, Medical Care, 45(S):S5-S8.
188. Lowes, B.D., Gilbert, E.M., Abraham, W.T., et al, 2002, Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents, New England Journal of Medicine, 346: 1357-1365.
189. Machin, D. and Campbell, M.J., 2005, Design of studies for medical research, Chichester, UK: John Wiley & Sons.
190. Malik, M. and Camm, A.J., 2001, Evaluation of drug-induced QT interval prolongation: Implications for drug approval and labelling, Drug Safety, 24: 323-351.
191. Mallal, S., Phillips, E., Carosi, G., et al. for the PRECICT-1 Study Team, 2008, HLA-B*570 1 screening for hypersensitivity to abacavir, New England Journal of Medicine, 358:568-579.
192. Mangano, D.T., Tudor, I.C., and Dietzel, C., for the Multicenter Study of Perioperative Ischemia Research Group and the Ischemia Research and Education Foundation, 2006, The risk associated with aprotinin in cardiac surgery, New England Journal of Medicine, 354:353-365.
193. Mann, R., and Andrews, E. (Eds.), 2002, Preface. Pharmacovigilance, Chichester, UK: John Wiley & Sons, xvii.
194. Mann, R. and Andrews, E. (Eds.), 2007a, Pharmacovigilance, 2nd edition, Chichester, UK: John Wiley & Sons.
195. Mann, R. and Andrews, E., 2007b, Introduction. In Mann, R. and Andrew, E. (Eds.), Pharmacovigilance, 2"d edition, Chichester, UK: John Wiley & Sons.
196. Marinker, M., 2004, From compliance to concordance: A personal view. In Bond, C. (Ed.), Concordance, London: Pharmaceutical Press, 1-7.
197. Marino, P., Simoni, J.M., and Silverstein, L.B., 2007, Peer support to promote medication adherence among people living with HIV/AIDS: The benefits to peers, Social Work in Health Care, 45:67-80.
198. Martin, E.W., 1978, Hazards of medications, Philadelphia, PA: J.B. Lippincott Company.
199. Martinez, M.N., 2005, Interspecies differences in physiology and pharmacology: Extrapolating preclinical data to human populations. In Rogge, M.C. and Taft, D.R. (Eds.), Preclinical drug development, Boca Raton, FL: Taylor & Francis, 11-66.
200. Mason, J.W., 2008, Reduce the number of ECGs: De$nitive QT study design, Presentation given at the CBI Second Annual Cardiac Safety Summit, Alexandria, VA, January 15,2008.
201. Matthews, J.N.S., 1999, Introduction to randomized controlled clinical trials, London: Edward Arnold.
202. Matthews, J.N.S., 2006, Introduction to randomized controlled clinical trials, 2"" edition, Boca Raton, FL: Chapman & HaWCRC.
203. Mead, N. and Bower, P., 2000, Patient-centredness: A conceptual framework and review of the empirical literature, Social Science and Medicine, 51: 1087-1110
204. Meyer, U.A., 2002, Introduction to pharmacogenomics: Promises, opportunities, and limitations. In Licinio, J. and Wong, M-L. (Eds.), Pharmacogenomics: The search for individualized therapies, Manheim: Wiley-VCH, 1-8.
205. Meyer, T., Sartipy, P., Blind, F., Leisgen, C., and Guenther, E., 2007, New cell models and assays in cardiac safety profiling, Expert Opinion on Drug Metabolism and Toxicology, 3:507-517.
206. Mitcheson, J., Perry, M., Stansfeld, P., et al., 2005, Structural determinants for highaffinity block of hERG potassium channels. In Chadwick, D.J. and Goode, J. (Eds.), Symposium on the hERG cardiac potassium channel: Structure, function, and long QTsyndrome, Chichester, UK: John Wiley & Sons, 136-150.
207. Monkhouse, D.C., 2006, Manufacturing and clinical medicine trends for the clinical trial material professional. In Monkhouse, D.C., Carney, C.F., and Clark, J.L. (Eds.), Drug products for clinical trials, 2nd edition, Boca Raton: Taylor & Francis, 21-68.
208. Moore, T.J., Cohen, M.R., and Furberg, C.D., 2007, Serious adverse drug events reported to the Food and Drug Administration 1998-2005, Archives of Znternal Medicine, 167: 1752-1759.
209. Moorman, A.F.M. and Christoffels, V.M., 2003, Development of the cardiac conduction system: A matter of chamber development. In Chadwick, D.J. and Goode, J. (Eds.), Development of the cardiac conduction system, Chichester, UK: John Wiley & Sons, 25-43.
210. Morganroth, J., Brozovich, F.V., McDonald, J.T., and Jacobs, R.A., 1991, Variability of the QT measurement in healthy men: With implications for selection of an abnormal QT value to predict drug toxicity and proarrhythmia, American Journal of Cardiology, 67:774-776.
211. Morganroth, J., 1993, Relations of QTc prolongation on the electrocardiogram to torsades de pointes: Definitions and mechanisms, American Journal of Cardiology, 72: 10B-13B.
212. Morganroth, J., 2005, Design and conduct of the Thorough Phase I ECG trial for new bioactive drugs. In Morganroth, J.M. and Gussak, I. (Eds.), Cardiac safety of noncardiac drugs: Practical guidelines for clinical research and drug development, Totowa, NJ: Humana Press Inc., 205-222.
213. Morganroth, J.M. and Gussak, I. (Eds.), 2005, Cardiac safety ofnoncardiac drugs: Practical guidelines,f or clinical research and drug development, Totowa, NJ: Humana Press Inc.
214. Mortara, J.L., 2005, ECG acquisition and signal processing: 12-lead ECG acquisition. In Morganroth, J.M. and Gussak, I. (Eds.), Cardiac sqfety of noncardiac drugs: Practical guidelines for clinical research and drug development, Totowa, NJ: Humana Press Inc., 131-145.
215. Mukherjee, D., Nissen, S.E., and Topol, E.J., 2001, Risk of cardiovascular events associated with selective COX-2 inhibitors, Journal of the American Medical Association, 286:954-959.
216. Mulder, G.J., 2006, Drug metabolism: Inactivation and bioactivation of xenobiotics. In Mulder, G.J. and Dencker, L. (Eds.), Pharmaceutical toxicology, London: Pharmaceutical Press, 41-66.
217. Murray, R.K., 2006, Glycoproteins. In Murray, R.K., Granner, D.K., and Rodwell, V.W. (Eds.), Harper j. illustrated biochemistry, 27Ih edition, New York: Lange Medical BooksiMcGraw-Hill, 523-544.
218. Murray, R.K. and Granner, D.K., 2006, Membranes: Structure and function. In Murray, R.K., Granner, D.K., and Rodwell, V.W. (Eds.), Harper i illustrated biochemistv, 271h edition, New York: Lange Medical Books/McGraw-Hill, 422-441.
219. Nada, A. and Somberg, J., 2007, First-in-man (FIM) clinical trials post-TeGenero: A review of the impact of the TeGenero trial on the design, conduct, and ethics of FIM trials, American Journal of Therapeutics, 14:594-604.
220. Nerbonne, J.M. and Kass, R.S., 2005, Molecular physiology of ion channels that control cardiac repolarization. In Morganroth, J.M. and Gussak, 1. (Eds.), Cardiac safety of noncardiac drugs: Practical guidelines for clinical research and drug development, Totowa, NJ: Humana Press Inc., 13-36.
221. Nesto, R.W., Bell, D., Bonow, R.O., et al., 2003, Thiazolidinedione u, fluid retention, and congestive heart failure: A consensus statement from the American Heart Association and the American Diabetes Association, October 7, 2003, Circulation, 108:2941-2948.
222. Nissen, S.E. and Wolski, K., 2007, Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes, New England Journal of Medicine, 356:2457-2471.
223. Norgrady, T. and Weaver, D.F., 2005, Medicinal chemistry: A molecular and biochemical approach, 3rd edition, Oxford: Oxford University Press.
224. Norris, S.L., Carson, S., and Roberts, C., 2007, Comparative effectiveness of pioglitazone and rosiglitazone in type 2 diabetes, prediabetes, and the metabolic syndrome: A meta-analysis, Current Diabetes Reviews, 3: 127-140.
225. Obrist, P.A., 1981, Cardiovascular psychophysiology: A perspective, New York: Plenum Press.
226. O'Donohue, W.T. and Levensky, E.R. (Eds.), 2006, Promoting treatment adherence: A practical handbook for health care providers, Thousand Oaks, CA: Sage Publications.
227. Ofran, Y. and Rost, B., 2005, Predictive methods using protein sequences. In Baxevanis, A.D. and Ouellette, B.F.F. (Eds.), Bioinformatics: A practical guide to the analysis of genes and proteins, 3rd edition, Hoboken, NJ: Wiley-Interscience, 197-221.
228. Ohnishi, K., Yoshida, H., Shigeno, K., et al., 2000, Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia, Annals of Internal Medicine, 133:881-885.
229. Oliver, J.J. and Webb, D.J., 2003, Surrogate endpoints. In Wilkins, M.R. (Ed.), Experimental therapeutics, London: Martin DunitziTaylor & Francis Group, 145-165.
230. Olsson, S. and Meyboom, R., 2006, Pharmacovigilance. In Mulder, G.J. and Dencker, L. (Eds.), Pharmaceutical toxicology, London: Pharmaceutical Press, 229-241.
231. O'Neill, R.T., 1987, Statistical analyses of adverse event data from clinical trials: Special emphasis on serious events, Drug Information Journal, 21:9-20.
232. O'Neill, R.T., 1995, Statistical concepts in the planning and evaluation of drug safety from clinical trials in drug development: Issues of international harmonization, Statistics in Medicine, 14: 1117-1127.
233. O'Neill, R.T., 1998, Biostatistical considerations in pharmacovigilance and pharmacoepidemiology: Linking quantitative risk assessment in pre-market licensure application safety data, post-market alert reports, and formal epidemiological studies, Statistics in Medicine, 17: 1851-1858.
234. O'Neill, R.T., 2008, A perspective on characterizing benefits and risks derived from clinical trials: Can we do more? Drug Information Journal, 42:235-245.
235. Osterberg, L. and Blaschke, T., 2005, Adherence to medication, New England Journal qf Medicine, 353:487-497.
236. Palladino, M.A., 2006, Understanding the human genome project, 2nd edition, San Francisco: PearsoniBenjamin Cummings.
237. Park, D.C. and Liu, L.L. (Eds.), 2007, Medical adherence and aging: Social and cognitive perspectives, Washington, DC: American Psychological Association.
238. Pasternak, J.J., 1999, Introduction to human molecular genetics: Mechanisms of inherited diseases, Hoboken, NJ: John Wiley & Sons.
239. Perrio, M., Voss, S., and Shakir, S.A., 2007, Application ofthe Bradford Hill criteria to assess the causality of cisapride-induced arrhythmia: A model for assessing causal association in pharmacovigilance, Drug Safety, 30:333-346.
240. [PhRMA] Pharmaceutical Research and Manufacturers of America QT Statistics Expert Working Team, 2005, Investigating drug-induced QT and QTc prolongation in the clinic: Review of statistical design and analysis considerations. Report from the Pharmaceutical Research and Manufacturers of America QT Statistics Expert Team, Drug Information Journal, 39:243-266.
241. Piantadosi, S., 2005, Clinical trials: A methodologic perspective, 2"d edition, Hoboken, NJ: Wiley-Interscience.
242. Pignone, M., 2007, Rosiglitazone appears to be associated with an increased risk of cardiovascular events, Clinical Diabetes, 25: 123-124.
243. Piper, D.R., Sanguinetti, M.C., and Tristani-Firouzi, M., 2005, Voltage sensor movement in the hERG K' channel. In Chadwick, D.J. and Goode, J. (Eds.), Svmposium on the hERG cardiac potassium channel: Structure, function, and long QTsvndrome, Chichester, UK: John Wiley & Sons, 46-52.
244. Primrose, S.B. and Twyman, R.M., 2006, Principles of gene manipulation and genomics, 7Ih edition. Malden, MA: Blackwell Publishing.
245. Rabinowitz, M. and Shankley, N., 2006, The impact of combinatorial chemistry on drug discovery. In Smith, C.G. and O'Donnell, J.T. (Eds.), The process of new drug discovery and development, 2"d edition, New York: Informa Healthcare, 55-77.
246. Raffa, R.B., Rawls, S.M., and Beyzarov, E.P., 2005, Netter k illustrated pharmacology, Philadelphia: SaundedElsevier.
247. Ray, W.A., 2008, Learning from aprotinin-Mandatory trials of comparative efficacy and safety are needed, New England Journal of Medicine, 358:840-842.
248. Recanatini, M., Cavalli, A., and Masetti, M., 2005, In silico modeling-Pharmacophores and hERG channel models. In Chadwick, D.J. and Goode, J. (Eds.), Symposium on the hERG cardiac potassium channel: Structure, function, and long QTsyndrome, Chichester, UK: John Wiley & Sons, 171-180.
249. Regulatory Affairs Professionals Society, 2005, Fundamentals of US regulatory affairs, Rockville, MD: Regulatory Affairs Professionals Society.
250. Regulatory Affairs Professionals Society, 2007, Fundamentals of US regulatory affairs, 5'h edition, Rockville, MD: Regulatory Affairs Professionals Society.
251. Rentschler, S., Morley, G.E., and Fishman, G.I., 2003, Patterning of the mouse conduction system. In Chadwick, D.J. and Goode, J. (Eds.), Development of the cardiac conduction system, Chichester, UK: John Wiley & Sons, 194-209.
252. Roberts, R.J., 1993, An amazing distortion in DNA induced by a methyltransferase. Nobel Lecture (Nobel Prize for Medicine), December 8. (http://nobelprize.org/nobelgrizes/medicine/laureates/1 993/roberts-lecture.pdf, accessed March 1 7, 2008.)
253. Robertson, G.A., Jones, E.M.C., and Wang, J., 2005, Gating and assembly of heteromeric hERG1ail b channels underlying ZKr in the heart. In Chadwick, D.J. and Goode, J. (Eds.), Symposium on the hERG cardiac potassium channel: Structure, function, and long QTsyndrome, Chichester, UK: John Wiley & Sons, 4-13.
254. Rodeheffer, R.J. and Redfield, M.M., 2007, Heart failure: Diagnosis and evaluation. In Murphy, J.G. and Lloyd, M.A. (Eds.), Mayo clinic cardiology: Concise textbook, 3rd edition, Rochester, MN: Mayo Clinic Scientific Press, 1101-1112.
255. Roden, D.M., 2004, Drug-induced prolongation of the QT interval, New England Journal of Medicine, 350: 1013-1022.
256. Rogge, M.C. and Taft, D.R. (Eds.), 2005, Preclinical drug development, Boca Raton, FL: Taylor & Francis Rolan, P.E. and Molnar, V., 2006, The assessment of pharmacokinetics in earlyphase drug evaluation. In Lee, C-J., Lee, L.H., Wu, C.L., Lee, B.R., and Chen, M-L. (Eds.), Clinical trials of drugs and biopharmaceuticals, Boca Raton, FL: Taylor & Francis, 123-132.
257. Rosen, C.J., 2007, Perspective: The rosiglitazone story-Lessons from and FDA advisory committee meeting, New England Journal of Medicine, 357:844-846.
258. Routledge, P., 2004, Adverse drug reactions and interactions: Mechanisms, risk factors, detection, management and prevention. In Talbot, J. and Waller, P. (Eds.), Stephens 'detection of new adverse drug reactions, 5Ih edition, Chichester, UK: John Wiley & Sons, 91-125.
259. Sager, P.T., Nebout, T., and Darpo, B., 2005, ICH E14: A new regulatory guidance on the clinical evaluation of QTiQTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs, Drug Information Journal, 39:387-394.
260. Sarapa, N., 2005, Digital 12-lead holter vs standard resting supine electrocardiogram for the assessment of drug-induced QTc prolongation: Assessment by different recording and measurement methods. In Morganroth, J.M. and Gussak, I. (Eds.), Cardiac safety of noncardiac drugs: Practical guidelines for clinical research and drug development, Totowa, NJ: Humana Press Inc., 147-166.
261. Satin, L., 2008, Issues in the Thorough QT Trial. Presentation given at the CBI 3'" Annual Conference on Cardiac Safety, Washington, DC, January 2008.
262. Schneeweiss, S., Seeger, J.D., Landon, J., and Walker, A.M., 2008, Aprotinin during coronary-artery bypass drafting and risk of death, New England Journal of Medicine, 358:771-783.
263. Schultz, R.M., 2006, Proteins 11: Structure-function relationships in protein families. In Devlin, T.M. (Ed.), Textbook of biochemistry with clinical correlations, 61h edition, Hoboken, NJ: John Wiley & Sons, 319-363.
264. Schultz, W.B., 2007, Perspective: Bolstering the FDA's drug-safety authority, New England Journal of Medicine, 357:2217-2219.
265. Schuster, D.P., 2005, Introduction: The value of translational and experimental clinical research. In Schuster, D.P. and Powers, W.J., Eds, Translational and experimental clinical research, Philadelphia: Lippincott Williams & Wilkins, xv-xxi.
266. Schwartz, P.J., 2005, The long QT syndrome: A clinical counterpart of hERG mutations. In Chadwick, D.J. and Goode, J. (Eds.), Symposium on the hERG cardiac potassium channel: Structure, function, and long QT s-vndrome, Chichester, UK: John Wiley & Sons, 186-198.
267. Senn, S., 2007, Statistical issues in drug development, 2"d edition, Chichester, UK: John Wiley & Sons.
268. Shah, R.R, 2005a, Interpretation of clinical ECG data: Understanding the risk from non-antiarrhythmic drugs. In Morganroth, J.M. and Gussak, I. (Eds.), Cardiac safety of noncardiac drugs: Practical guidelines for clinical research and drug development, Totowa, NJ: Humana Press lnc., 259-298.
269. Shah, R.R., 2005b, Drug-induced QT interval prolongation: Regulatory guidance and perspectives on hERG channel studies. In Chadwick, D.J. and Goode, J. (Eds.), Symposium on the hERG cardiac potassium channel: Structure, function, and long QT syndrome, Chichester, UK: John Wiley & Sons, 251-280.
270. Shah, R.R., 2007a, Cardiac repolarisation and drug regulation: Assessing cardiac safety 10 years after the CPMP guidance, Drug Safety, 30: 1093-1110.
271. Shah, R.R., 2007b, Withdrawal of terodiline: A tale of two toxicities. In Mann, R. and Andrews, E. (Eds.), Pharmacovigilance, 2"d edition, Chichester, UK: John Wiley & Sons, 109-136.
272. Shakir, S.A.W., 2007, PEM in the UK. In Mann, R. and Andrews, E. (Eds.), Pharmacovigilance, 2"d edition, Chichester, UK: John Wiley & Sons, 307-316.
273. Shakir, S.A. and Layton, D., 2002, Causal association in pharmacovigilance and pharmacoepidemiology: Thoughts on the application of the Austin Bradford-Hill criteria, Drug Safety, 25:467-471.
274. Silverstein, F.E., Faich, G., Goldstein, J.L., et al., 2000, Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs of osteoarthritis and rheumatoid arthritis. The CLASS study: A randomized controlled trial, Journal of the American Medical Association, 284: 1247-1255.
275. Simko, J., Csilek, A., Karaszi, and Lorincz, I., 2008, Proarrhythmic potential of antimicrobial agents, Infection, May 3 [E-publication ahead of print].
276. Simoni, J.M., Pantalone, D.W., Plummer, M.D., and Huang, B., 2007,A randomized controlled trial of a peer support intervention targeting antiretroviral medication adherence and depressive symptomatology in HIV-positive men and women, Health Psychology, 26:488-495.
277. Simons, L.E. and Blount, R.L., 2007, Identifying barriers to medication adherence in adolescent transplant recipients, Pediatric Psychology, 32:831-844.
278. Singh, S., Loke, Y.K., and Furberg, C.D., 2007, Long-term risk of cardiovascular events with rosiglitazone: A meta-analysis, Journal of the American Medical Association, 298: 1189-1195.
279. Smetzer, J.L., 2007, Managing medication risks through a culture of safety. In Cohen, M.R. (Ed.), Medication Errors, 2"d edition, Washington, DC: American Pharmacists Association. 605-654.
280. Smith, C.G. and O'Donnell, J.T. (Eds.), 2006, The process ofnew drug discovery and development, 2"d edition, New York: Informa Healthcare USA.
281. Soloviev, M.V., Barry, R., and Terrett, J., 2004, Chip based proteomics technology. In Rapley, R. and Harbron, S. (Eds.), Molecular analysis andgenome discovery, Chichester, UK: John Wiley & Sons, 217-249.
282. Soloviev, M.V., Hamlin, R.L., Shellhammer, L.J., et al., 2006, Variations in hemodynamic and ECG in healthy, conscious, freely moving telemetrized beagle dogs, Cardiovascirlar Toxicology, 6:51-62.
283. Stephens, M.D.B., 2004, Introduction. In Talbot, J. and Waller, P. (Eds.), Stephens' detection ofnew adverse drug reactions, 51h edition, Chichester, UK: John Wiley & Sons. 1-90.
284. Stevens, M. and Roberts, C., 2007, The impact of future trends in new sciences on the practising pharmacist, The Pharmaceutical Journal, 279:273-274.
285. Stevenson, F., 2004, The patient's perspective. In Bond, C. (Ed.), Concordance, London: Pharmaceutical Press, 29-47.
286. Stewart, L.A. and Clarke, M.J., 1995, Practical methodology of meta-analyses (overviews) using updated individual patient data, Statistics in Medicine, 14: 2057-2079.
287. Stewart, L., Tierney, J., and Burdett, S., 2005, Do systematic reviews based on individual patient data offer a means of circumventing biases associated with trial publications? In Rothstein, H.R., Sutton, A.J., and Borenstein, M., (Eds.), Publication bias in meta-analysis: Prevention, assessment and adjustments, Chichester, UK: John Wiley & Sons, p. 262-286.
288. Stewart, L.A. and Clarke, M.J., 1995, Practical methodology of meta-analyses (overviews) using updated individual patient data, Statistics in Medicine, 14: 2057-2079.
289. Strom, B.L. (Ed.), 2005a, Pharmacoepiderniology, qLh edition, Chichester, UK: John Wiley & Sons, 29-36.
290. Strom, B.L., 2005b, Sample size considerations for pharmacoepidemiology studies. In Strom, B.L. (Ed.), Pharmacoepidemiology, 4th edition, Chichester, UK: John Wiley & Sons, 29-36.
291. Strom, B.L., 2007, Methodologic challenges to studying patient safety and comparative effectiveness, Medical Care, 45(10 Suppl. 2):s13-S15.
292. Sullivan, S.D., Kreling, D.H., Hazlet, T.K., et al., 1990, Noncompliance with medication regimes and subsequent hospitalizations: A literature analysis and cost of hospitalization estimate, Journal of Research in Pharmaceutical Economics, 2: 19-33.
293. Takemasa, H., Nagatomo, T., Abe, H., et al., 2008, Coexistence of hERG current block and disruption of protein trafficking in ketoconazole-induced long QT syndrome, British Journal of Pharmacology, 153:439-447.
294. Talbot, J. and Stephens, M.D.B., 2004, Clinical trials: Collection of safety data and establishing the adverse drug reaction profile. In Talbot, J. and Waller, P. (Eds.), Stephens 'detection of new adverse drug reactions, Sh edition, Chichester, UK: John Wiley & Sons, 167-242.
295. Talbot, J. and Waller, P. (Eds.), 2004, Stephens ' detection of new adverse drug reactions, 5'h edition, Chichester, UK: John Wiley & Sons.
296. Taylor, M.R. and Bristow, M.R., 2006, Alterations in myocardial gene expression as a basis for cardiomyopathies and heart failure. In Bock, G. and Goode, J. (Eds.), Heart failure: Molecules, mechanisms and therapeutic tatgets, Chichester, UK: John Wiley & Sons, 73-89.
297. Thomas, G., 2003, Fundamentals of medicinal chemistry, Chichester, UK: John Wiley & Sons.
298. Tisdale, J.E., Kovacs, R., Mi, D., et a]., 2007, Accuracy of uncorrected versus corrected QT interval for prediction of torsade de pointes associated with intravenous haloperidol, Pharmacotherapy, 27: 175-182.
299. Tozer, T.N. and Rowland, M., 2006, Introduction to pharmacokinetics and pharmacodynamics: The quantitative basis of drug therapy, Lippincott Williams & Wilkins.
300. Triggle, D.J., Gopalakrishnan, M., Rampe, D., andZheng, W. (Eds.), 2006, Voltugegated ion channels us drug targets, Weinheim, Germany: Wiley-VCH.
301. Tseng, G.N. and Guy, H.R., 2005, Structure-function studies of the outer mouth and voltage sensor domain of hERG. In Chadwick, D.J. and Goode, J. (Eds.), Symposium on the hERG cardiac potassium channel: Structure, function, and long QTsyndrome, Chichester, UK: John Wiley & Sons, 19-35.
302. Tsong, Y., Shen, M., Zhong, J., and Zhang, J., 2008, Statistical issues of QT prolongation assessment based on linear concentration modeling, Journal of Biopharmaceutical Statistics, 1S(3): 564-84.
303. Turner, J. R., 1994, Cardiovascular reactivity and stress: Patterns ofphysiological response, New York: Plenum Press.
304. Turner, J.R., 2007, New drug development: Design, methodology, and analysis, Hoboken, NJ: John Wiley & Sons.
305. van der Heyden, M.A., Smits, M.E., and Vos, M.A., 2008, Drugs and trafficking of ion channels: A new proarrhythmic threat on the horizon, British Journal of Pharmacology, 153:406-409.
306. van der Laan, J. W., 2006, Safety assessment of pharmaceuticals: Regulatory aspects. In Mulder, G.J. and Dencker, L. (Eds.), Pharmaceutical toxicology, London: Pharmaceutical Press, 209-227.
307. Vargas, H., 2008, Proarrhythmic liability of large-molecule drugs. Presentation given during a Webinar entitled Cardiac safety in large molecules: New regulatory expectations, new strategies, February 26 [see Section 7.20 for more details].
308. Vargas, H.M., Bass, A.S., Breidenbach, A., et al., 2008, Scientific review and recommendations on preclinical cardiovascular safety evaluation of biologics, Journal of Pharmacological and Toxicological Methods, April 18 [ E-publication ahead of print].
309. Venter, J.C., Adams, M.D., Myers, E.W., et al., 2001, The sequence of the human genome, Science, 29 1: 1304-1351.
310. Vlahakes, G.J., 2006, Editorial: The value of Phase 4 clinical testing, New England Journal of Medicine, 354:413-415.
311. Wadman, M., 2007, Experts call for active surveillance of drug safety, Nature, 446: 358-359.
312. Walsh, G., 2003, Biopharmaceuticals: Biochemistry and biotechnology, 2nde dition, Chichester, UK: John Wiley & Sons.
313. Walsh, G., 2007, Pharmaceutical biotechnology: Concepts and applications, Chichester, UK: John Wiley & Sons.
314. Wang, Q., Shen, J., Splawski I., et al., 1995, SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome, Cell, 802:305-811.
315. Watson, J.D., 2004, DNA: The secret of life, New York: Alfred A. Knopf.
316. Weaver, K.E., Llabre, M.M., Duran, R.E, et al., 2005, A stress and coping model of medication adherence and viral load in HIV-positive men and women on highly active antiretroviral therapy (HAART), Health Psychology, 24:385-392.
317. Webb, P., Bain, C., and Pirozzo, S., 2005, Essential epidemiology: An introduction for students and health professionals, Cambridge, UK: Cambridge University Press.
318. Weiner, H, 2006, Enzymes: Classification, kinetics, and control. In Devlin, T.M. (Ed.), Textbook of biochemistry with clinical correlations, 6Ih edition, Hoboken, NJ: Wiley-LISS, 365-412.
319. Weir, M.R., Sperling, R.S., Reicin, A., and Gertz, B.J., 2003, Selective COX-2 inhibition and cardiovascular effects: A review of the rofecoxib development program, American Heart Journal, 146:591-604.
320. West, L.J., 1991, Medicines Control Agency (MCA) and other regulatory authorities. In International Drug Surveillance Department (IDSD), Glaxo Group Research, Drug sufety: A shared responsibility, New York: Churchill Livingstone, 89-97.
321. Westfall, P.H., Tobias, R.D., Rom, D., Wolfinger, R.D., and Hochberg, Y., 1999, Multiple comparisons and multiple tests using SAP, Cary, NC: SAS Institute.
322. Whitehead, A., 2002, Meta-analysis of controlled clinical trials, Hoboken, NJ: John Wiley & Sons.
323. WHO, 2002, The importance ofpharmacovigilance: Safety monitoring of medicinal products, Geneva: World Health Organization (see http:llwww.who.intlen/).
324. WHO, 2003, Adherence to long-term therapies: Evidence for action, Geneva: World Health Organization (see http:llwww.who.intleni).
325. WHO, 2004, Pharmacovigilance: Ensuring the safe use of medicines, Geneva: World Health Organization (see http:llwww.who.intien/).
326. Wijnen, P.A., Op den Buijsch, R.A., Drent, M., et al., 2007, Review article: The prevalence and clinical relevance of cytochrome P450 polymorphisms, Aliment Pharmacology and Therapeutics, 26(S2):211-219.
327. Wild, R.N., 2007, Micturin and torsades de pointes. In Mann, R. and Andrews, E. (Eds.), Pharmacovigilance, 2"d edition, Chichester, UK: John Wiley & Sons, 105-108.
328. Wishart, D., 2005, protein structure and analysis. In Baxevanis, A.D. and Ouellette, B.F.F. (Eds.), Bioinformutics: A practical guide to the analysis of genes and proteins, 3rd edition, Hoboken, NJ: Wiley-Interscience, 223-251.
329. Wolfe, M.M., Ding, E.L., and Song, Y., 1999, Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs, New England Journal of Medicine, 340: 1888-1899.
330. Wood, A.J.J., 2006, Sounding board: A proposal for radical changes in the drugapproval process, New England Journal of Medicine, 355:618-623.
331. Woodward, M., 2005, Epidemiology: Study design and data analysis, 2"d edition, Boca Raton, FL: Chapman & HalllCRC.
332. Wozniacka, A., Cygankiewicz, I., Chudzik, M., Sysa-Jedrzejowska, A., and Wranicz, J.K., 2006, The cardiac safety of chloroquine phosphate treatment in patients with systemic lupus erythematosus: The influence on arrhythmia, heart rate variability and repolarization parameters, Lupus, 15:521-525.
333. Yap, Y.G. and Camm, A.J., 2002, Drug-induced long QTsyndrome, Armonk, NY: Futura Publishing Company.
334. Yasumura, Y., Takemura, K., Sakamoto, A., Kitakaze, M., and Miyatake, K., 2003, Changes in myocardial gene expression associated with beta-blocker therapy in patients with chronic heart failure, Journal of Cardiac Failure, 9:469-474.
335. Yi, H., Cao, Z., Dai, C., Wu, Y., and Li, W., 2007, Interaction simulation of hERG K+ channel with its specific BeKm-1 peptide: Insights into the selectivity of molecular recognition, Journal of Proteome Research, 6:611-620.
336. Yilmaz, U., Oztop, I., Ciloglu, A,, et al., 2007, 5-flourouracil increases the number and complexity of premature complexes in the heart: A prospective study using ambulatory ECG monitoring, International Journal of Clinical Practice, 61: 795-801.
337. Zhang, J., 2008, Study design, sample size and assay sensitivity in TQT studies, Presentation given at the 2"d Annual Summit on Cardiac Safety, Alexandria, VA, January 14-15.
338. Zhang, M., Korolkova, Y.V., Liu, J., et al., 2003, BeKm-1 is a hERG-specific toxin that shares the structure with ChTx but the mechanism of action with ErgTxl, Biophysical Journal, 84:3022-3036.
339. Zhou, J., Augelli-Szafran, C.E., Bradley, J.A., et al., 2005, Novel potent human ether-a-go-go-related gene (hERG) potassium channel enhancers and their in vitro anti-arrhythmogenic activity, Moleculav Pharmacology, 68:876-884.